Article Type
Changed
Fri, 01/04/2019 - 11:11
Display Headline
David Henry's JCSO podcast, September 2015

For the September podcast for The Journal of Community and Supportive Oncology, Dr David Henry discusses 3 Original Reports: one on identifying the risk factors for hospital readmission among patients who have received a hematopoietic stem cell transplant and designing preventive measures to lower those risks and related readmissions; a second that focuses on young women with breast cancer who are from diverse populations and who face specific challenges in regard to their existing support systems and unmet needs for information and support; and the third that examines the effects of a self-care education program on the quality of life of in patients with gastric cancer after they have undergone gastrectomy. Dr Henry also highlights this month’s Community Translations article on the approval of nivolumab, the first immunotherapy to receive the go-ahead from the Food and Drug Administration for the treatment of for lung cancer, specifically, squamous cell non-small-cell lung cancer, and an accompanying Commentary by Dr Kartik Konduri. The podcast is rounded off with comments on an essay about the shift from practicing oncology as a generalist to the current more prevalent tendency to subspecialize, and an argument suggesting that the generalist approach offers a potentially useful perspective to help make sense of what can seem like an overwhelming amount of data on emerging new therapies and understanding of tumor biology.

 

Click on the download icon at the top of this introduction to listen to the podcast.

 

Audio / Podcast
Publications
Legacy Keywords
hospital readmissions, hematopoietic stem cell transplant, HSCT, autologous transplant, allogeneic transplant, graft-versus-host disease, length of stay, LoS, increased risk for readmission, unrelated donor, nonmyeloablative conditioning, predischarge education, leukemia, lymphoma, myelodysplasia, MDS, myeloproliferative disease, MPD, myeloma, aplastic anemia, paroxysmal nocturnal hemoglobinuria, medulloblastoma, breast cancer, stage I-III invasive breast cancer, treatment-related changes, fertility, menopause, transitioning into survivorship, gastrectomy, quality of life, QoL, gastric cancer, self-care education program, QLQ-C30, QLQ-STO22, nivolumab, squamous cell, non-small-cell lung cancer, NSCLC, immunotherapy, lung cancer, programmed cell death-1, PD-1, immune checkpoint, T cells, CheckMate017, docetaxel, paclitaxel therapy, bevacizumab, imatinib, everolimus, generalist, subspecialist, abiraterone, enzalutamide, sipuleucel-T, docetaxel, cabazitaxel, radium 223, chemotherapy holiday, postoperative radiation, metastatectomy, incidentalomas, anti-VEGF, disease-remitting therapies
Sections
Audio / Podcast
Audio / Podcast

For the September podcast for The Journal of Community and Supportive Oncology, Dr David Henry discusses 3 Original Reports: one on identifying the risk factors for hospital readmission among patients who have received a hematopoietic stem cell transplant and designing preventive measures to lower those risks and related readmissions; a second that focuses on young women with breast cancer who are from diverse populations and who face specific challenges in regard to their existing support systems and unmet needs for information and support; and the third that examines the effects of a self-care education program on the quality of life of in patients with gastric cancer after they have undergone gastrectomy. Dr Henry also highlights this month’s Community Translations article on the approval of nivolumab, the first immunotherapy to receive the go-ahead from the Food and Drug Administration for the treatment of for lung cancer, specifically, squamous cell non-small-cell lung cancer, and an accompanying Commentary by Dr Kartik Konduri. The podcast is rounded off with comments on an essay about the shift from practicing oncology as a generalist to the current more prevalent tendency to subspecialize, and an argument suggesting that the generalist approach offers a potentially useful perspective to help make sense of what can seem like an overwhelming amount of data on emerging new therapies and understanding of tumor biology.

 

Click on the download icon at the top of this introduction to listen to the podcast.

 

For the September podcast for The Journal of Community and Supportive Oncology, Dr David Henry discusses 3 Original Reports: one on identifying the risk factors for hospital readmission among patients who have received a hematopoietic stem cell transplant and designing preventive measures to lower those risks and related readmissions; a second that focuses on young women with breast cancer who are from diverse populations and who face specific challenges in regard to their existing support systems and unmet needs for information and support; and the third that examines the effects of a self-care education program on the quality of life of in patients with gastric cancer after they have undergone gastrectomy. Dr Henry also highlights this month’s Community Translations article on the approval of nivolumab, the first immunotherapy to receive the go-ahead from the Food and Drug Administration for the treatment of for lung cancer, specifically, squamous cell non-small-cell lung cancer, and an accompanying Commentary by Dr Kartik Konduri. The podcast is rounded off with comments on an essay about the shift from practicing oncology as a generalist to the current more prevalent tendency to subspecialize, and an argument suggesting that the generalist approach offers a potentially useful perspective to help make sense of what can seem like an overwhelming amount of data on emerging new therapies and understanding of tumor biology.

 

Click on the download icon at the top of this introduction to listen to the podcast.

 

Publications
Publications
Article Type
Display Headline
David Henry's JCSO podcast, September 2015
Display Headline
David Henry's JCSO podcast, September 2015
Legacy Keywords
hospital readmissions, hematopoietic stem cell transplant, HSCT, autologous transplant, allogeneic transplant, graft-versus-host disease, length of stay, LoS, increased risk for readmission, unrelated donor, nonmyeloablative conditioning, predischarge education, leukemia, lymphoma, myelodysplasia, MDS, myeloproliferative disease, MPD, myeloma, aplastic anemia, paroxysmal nocturnal hemoglobinuria, medulloblastoma, breast cancer, stage I-III invasive breast cancer, treatment-related changes, fertility, menopause, transitioning into survivorship, gastrectomy, quality of life, QoL, gastric cancer, self-care education program, QLQ-C30, QLQ-STO22, nivolumab, squamous cell, non-small-cell lung cancer, NSCLC, immunotherapy, lung cancer, programmed cell death-1, PD-1, immune checkpoint, T cells, CheckMate017, docetaxel, paclitaxel therapy, bevacizumab, imatinib, everolimus, generalist, subspecialist, abiraterone, enzalutamide, sipuleucel-T, docetaxel, cabazitaxel, radium 223, chemotherapy holiday, postoperative radiation, metastatectomy, incidentalomas, anti-VEGF, disease-remitting therapies
Legacy Keywords
hospital readmissions, hematopoietic stem cell transplant, HSCT, autologous transplant, allogeneic transplant, graft-versus-host disease, length of stay, LoS, increased risk for readmission, unrelated donor, nonmyeloablative conditioning, predischarge education, leukemia, lymphoma, myelodysplasia, MDS, myeloproliferative disease, MPD, myeloma, aplastic anemia, paroxysmal nocturnal hemoglobinuria, medulloblastoma, breast cancer, stage I-III invasive breast cancer, treatment-related changes, fertility, menopause, transitioning into survivorship, gastrectomy, quality of life, QoL, gastric cancer, self-care education program, QLQ-C30, QLQ-STO22, nivolumab, squamous cell, non-small-cell lung cancer, NSCLC, immunotherapy, lung cancer, programmed cell death-1, PD-1, immune checkpoint, T cells, CheckMate017, docetaxel, paclitaxel therapy, bevacizumab, imatinib, everolimus, generalist, subspecialist, abiraterone, enzalutamide, sipuleucel-T, docetaxel, cabazitaxel, radium 223, chemotherapy holiday, postoperative radiation, metastatectomy, incidentalomas, anti-VEGF, disease-remitting therapies
Sections
Disallow All Ads
Alternative CME